[1] |
Maurer M, Church MK, Gonçalo M, et al. Management and treatment of chronic urticaria (CU)[J]. J Eur Acad Dermatol Venereol, 2015,29 Suppl 3:16⁃32. doi: 10.1111/jdv.13198.
|
[2] |
D′Amato G, Stanziola A, Sanduzzi A, et al. Treating severe allergic asthma with anti⁃IgE monoclonal antibody (omalizumab): a review[J]. Multidiscip Respir Med, 2014,9(1):23. doi: 10.1186/2049⁃6958⁃9⁃23.
|
[3] |
Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria[J]. Ann Allergy Asthma Immunol, 2007,99(2):190⁃193. doi: 10.1016/S1081⁃1206(10)60644⁃8.
|
[4] |
Godse KV. Omalizumab in severe chronic urticaria[J]. Indian J Dermatol Venereol Leprol, 2008,74(2):157⁃158.
|
[5] |
Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
|
[6] |
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell FcεRI and function[J]. J Allergy Clin Immunol, 2004,114(3):527⁃530. doi: 10.1016/j.jaci. 2004.06.032.
|
[7] |
Hsu CL, Shiung YY, Lin BL, et al. Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model[J]. Int Immunopharmacol, 2010,10(4):533⁃539. doi: 10. 1016/j.intimp.2010.02.001.
|
[8] |
Kalesnikoff J, Huber M, Lam V, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival[J]. Immunity, 2001,14(6):801⁃811.
|
[9] |
Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2015,135(2):337⁃342. doi: 10.1016/j.jaci.2014.04.036.
|
[10] |
Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells[J]. Clin Transl Allergy, 2013,3(1):29. doi: 10.1186/2045⁃7022⁃3⁃29.
|
[11] |
Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo⁃controlled, dose⁃ranging study of single⁃dose omalizumab in patients with H1⁃antihistamine⁃refractory chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2011,128(3):567⁃573.e1. doi: 10.1016/j.jaci.2011.06.010.
|
[12] |
Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2017,139(3):1059⁃1061.e1. doi: 10.1016/j.jaci.2016.07.047.
|
[13] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and Update[J]. Allergy, 2018. doi: 10.1111/all.13397.
|
[14] |
Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2017,140(6):1749⁃1751. doi: 10.1016/j.jaci.2017.08.007.
|
[15] |
Fine LM, Bernstein JA. Urticaria guidelines: consensus and controversies in the European and American guidelines[J]. Curr Allergy Asthma Rep, 2015,15(6):30. doi: 10.1007/s11882⁃015⁃0535⁃z.
|
[16] |
McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria[J]. Drugs, 2014,74(14):1693⁃1699. doi: 10.1007/s40265⁃014⁃0290⁃9.
|
[17] |
Labrador⁃Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria[J]. Drug Des Devel Ther, 2015,9:4909⁃4915. doi: 10.2147/DDDT.S56004.
|
[18] |
Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306.
|
[19] |
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa1215372.
|
[20] |
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy[J]. J Allergy Clin Immunol, 2013,132(1):101⁃109. doi: 10.1016/j.jaci.2013.05.013.
|
[21] |
Casale TB, Bernstein JA, Maurer M, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy[J]. J Allergy Clin Immunol Pract, 2015,3(5):743⁃750.e1. doi: 10.1016/j.jaip.2015.04.015.
|
[22] |
Giménez⁃Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety[J]. Expert Opin Biol Ther, 2017,17(3):375⁃385. doi: 10.1080/14712598.2017. 1285 903.
|
[23] |
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti⁃IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma[J]. J Allergy Clin Immunol, 2001,108(2):184⁃190. doi: 10.1067/mai.2001.117880.
|
[24] |
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials[J]. J Allergy Clin Immunol, 2016,137(6):1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
|
[25] |
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032.
|